Raltegravir
- Generic Name
- Raltegravir
- Brand Names
- Isentress
- Drug Type
- Small Molecule
- Chemical Formula
- C20H21FN6O5
- CAS Number
- 518048-05-0
- Unique Ingredient Identifier
- 22VKV8053U
- Background
Raltegravir is an antiretroviral drug produced by Merck & Co., used to treat HIV infection. It received approval by the U.S. Food and Drug Administration (FDA) on 12 October 2007, the first of a new class of HIV drugs, the integrase inhibitors, to receive such approval.
- Indication
For the treatment of HIV-1 infection in conjunction with other antiretrovirals.
- Associated Conditions
- Human Immunodeficiency Virus Type 1 (HIV-1) Infection
- Associated Therapies
- Post-exposure prophylaxis for occupational exposure to HIV therapy
Antiretroviral Therapy Intensification With Raltegravir or Addition of Hyper-immune Bovine Colostrum in HIV-1 Infected Patients With Suboptimal CD4+ T Cell Response
- First Posted Date
- 2008-10-15
- Last Posted Date
- 2012-08-24
- Lead Sponsor
- Kirby Institute
- Target Recruit Count
- 75
- Registration Number
- NCT00772590
Effects of Raltegravir (Isentress®) on Lipid and Carbohydrate Metabolism and Mitochondrial Function in Healthy Volunteers
- Conditions
- First Posted Date
- 2008-10-15
- Last Posted Date
- 2010-03-31
- Lead Sponsor
- Hospital Clinic of Barcelona
- Target Recruit Count
- 14
- Registration Number
- NCT00772720
- Locations
- 🇪🇸
Hospital Clinic, Barcelona, Catalonia, Spain
Phase IIB Pilot of Atazanavir + Raltegravir
- Conditions
- Interventions
- First Posted Date
- 2008-10-08
- Last Posted Date
- 2012-02-24
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 167
- Registration Number
- NCT00768989
- Locations
- 🇺🇸
Orlando Immunology Center, Orlando, Florida, United States
🇫🇷Local Institution, Paris Cedex 20, France
🇺🇸Yale University School Of Medicine, New Haven, Connecticut, United States
Abacavir Pharmacokinetic Study in the Absence/Presence of Darunavir/Ritonavir or Raltegravir in HIV-infected Subjects
- First Posted Date
- 2008-10-02
- Last Posted Date
- 2009-11-18
- Lead Sponsor
- St Stephens Aids Trust
- Target Recruit Count
- 29
- Registration Number
- NCT00765271
- Locations
- 🇬🇧
Chelsea and Westminster Hospital, London, United Kingdom
BRAVO: Background Regimen of Raltegravir on Virologic Outcome
- First Posted Date
- 2008-09-12
- Last Posted Date
- 2017-07-02
- Lead Sponsor
- Community Research Initiative of New England
- Target Recruit Count
- 442
- Registration Number
- NCT00751530
- Locations
- 🇺🇸
Dr. Nicholaos C. Bellos & Associates, Dallas, Texas, United States
🇺🇸Light Source Medical, Los Angeles, California, United States
🇺🇸Quest Clinical Research, San Francisco, California, United States
Pharmacokinetic Study of Raltegravir in Healthy Premenopausal Women.
- First Posted Date
- 2008-09-04
- Last Posted Date
- 2012-10-15
- Lead Sponsor
- University of North Carolina, Chapel Hill
- Target Recruit Count
- 7
- Registration Number
- NCT00746499
- Locations
- 🇺🇸
University of North Carolina, Chapel Hill, North Carolina, United States
Comparing Raltegravir Genital Tract Distribution in HIV-infected Men and Women
- First Posted Date
- 2008-09-03
- Last Posted Date
- 2012-10-10
- Lead Sponsor
- University of Rochester
- Target Recruit Count
- 28
- Registration Number
- NCT00745368
- Locations
- 🇺🇸
University of Rochester, Rochester, New York, United States
Assess the Downregulation of HIV-1 When Raltegravir is Added to a Virologically Suppressed HAART Regimen
- First Posted Date
- 2008-08-20
- Last Posted Date
- 2021-01-19
- Lead Sponsor
- National Jewish Health
- Target Recruit Count
- 30
- Registration Number
- NCT00738569
- Locations
- 🇺🇸
National Jewish Health, Denver, Colorado, United States
Pilot Study of Raltegravir/Truvada Versus Efavirenz/Truvada for Adults With Acute IV-1 Infection
- Conditions
- Interventions
- First Posted Date
- 2008-08-14
- Last Posted Date
- 2016-05-30
- Lead Sponsor
- University of Alabama at Birmingham
- Target Recruit Count
- 18
- Registration Number
- NCT00734344
- Locations
- 🇺🇸
UAB 1917 Clinic, Birmingham, Alabama, United States
Genetic Predictors of Raltegravir Penetration Into Cerebrospinal Fluid
- First Posted Date
- 2008-08-08
- Last Posted Date
- 2015-03-03
- Lead Sponsor
- Vanderbilt University
- Target Recruit Count
- 40
- Registration Number
- NCT00729924
- Locations
- 🇺🇸
Vanderbilt Therapeutics Clinical Research Site, Nashville, Tennessee, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.